Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ribavirin hepatitis

Clinical trials in Bra2H in 1977 of the oral adininistration of ribavirin prompted the Bra2iUan government to approve its use for treating infectious hepatitis A (126). Because ribavirin is water-soluble, it can be dispersed readily in a fine-particle aerosol. Clinical trials (127) indicate that such aerosols... [Pg.312]

Although the term nucleoside was once limited to the compounds in Table 28.2 and a few others, cunent use is more permissive. Pyrimidine derivatives of D-arabinose, for exfflnple, occur in the free state in certain sponges and are called spongonticleosides. The powerful antiviral drug ribavirin, used to treat hepatitis C and Lassa fever, is a synthetic nucleoside analog in which the base, rather than being a pyrimidine or purine, is a triazole. [Pg.1160]

Ribavirin, an antiviral agent used against hepatitis C and viral pneumonia, contains a 1,2,4-triazole ring. Why is the ring aromatic ... [Pg.544]

Similar to HBV, infections with hepatitis C virus (HCV) have a high rate of progression from an acute to a chronic state that frequently leads to cirrhosis or hepatocellular carcinoma [2]. Monotherapy for HCV infection with IFN-a or combined therapy with ribavirin and IFN-a is associated with initial rates of response as high as 40%. The rates of sustained responses are, however, lower and also depend on the viral genotype. In patients infected with HCV genotype 2 or 3, the response was maximal after 24 weeks of treatment, whereas patients infected with genotype 1 -the most frequent in the USA and Europe - required a minimum treatment course of 48 weeks for an optimal outcome. [Pg.645]

Hoofnagle JH, Seeff LB (2006) Peginterferon and ribavirin for chronic hepatitis C. New Engl J Med 355 2444-2451... [Pg.23]

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet 358 958-965... [Pg.23]

Coelmont L, Paeshuyse J, Windisch MP, De Clercq E, Bartenschlager R, Neyts J (2006) Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2 -C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 50 3444-3446 D Abramo CM, Cellai L, GOtte M (2004) Excision of incorporated nucleotide analogue chain-terminators can diminish their inhibitory effects on viral RNA-dependent RNA polymerases. J Mol Biol 337 1-14... [Pg.80]

Jacobson IM, Everson GT, Gordon SC, Kauffman R, McNair L, Muir A, McHutchison JG (2007) Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive subjects with hepatitis C. AASLD 58th Annual Meet, Abstract 177 Johnson M (2006) Response to Atazanavir/ritonavir versus lopinavir/ritonavir equivalent or different efficacy profiles by HUl. AIDS 20 1987... [Pg.105]

HCV infection is rarefy diagnosed in the acute phase, as most acutely infected individuals are asymptomatic. Between 50% and 90% of patients develop chronic infection, however, and this warrants early therapy. After occupational exposure with a known date, treatment should not be started before the acute episode characterized by alanine aminotransferase elevation, but it should always be started within 24 weeks after the onset of symptoms. The optimal treatment schedule for acute hepatitis C is controversial. Pegylated IFN-a monotherapy at the standard dose for 24 weeks yielded SVR rates close to 100% in symptomatic patients referred to tertiary care centers (De Rosa et al. 2006 Jaeckel et al. 2001 Santantonio et al. 2005 Wiegand et al. 2006). Shorter therapy may be envisaged (Calleri et al. 2007). Combination with ribavirin is recommended if a first course of pegylated IFN-a monotherapy fails to eradicate the infection. Viral elimination appears to be independent of the HCV genotype and the HCV RNA level (Calleri et al. 2007 De Rosa et al. 2006 Jaeckel et al. 2001). [Pg.217]

Drugs such as ribavirin that may directly reduce FIDV replication and specific inhibitors of HBV replication such as lamivudine and adefovir dipivoxU have been tested in combination with IFN-a in patients with chronic hepatitis D. [Pg.227]

Thus, ribavirin is ineffective in chronic hepatitis D, whether given alone or in combination with IFN-a. [Pg.228]

Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, PeUiceUi A, Grisorio B, Barbarini G (1999) Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scand J Gastroenterol 34 928-933... [Pg.230]

Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Lohr HF, Galle PR (2006) Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 26 319-325... [Pg.231]

BriUanti S, Garson J, FoU M, Whitby K, Deaville R, Masci C, MigUoU M, Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107 812-817... [Pg.231]

Fried MW, Shiftman ML, Reddy KR, Smith C, Marinos G, Goncales EL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 975-982... [Pg.233]

Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Eabiano A, Bonino E, Rizzetto M, Verme G, Craxi A et al (1994) Ribavirin treatment for chronic hepatitis D a pilot study. Liver 14 154-157... [Pg.233]

Gunsar E, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, liter T, Batur Y (2005) Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 10 721-726 Habersetzer E, Boyer N, MarceUin P, Badly F, Ahmed SN, Alam J, Benhamou JP, Trepo C (2000) A pdot study of recombinant interferon beta-la for the treatment of chronic hepatitis C. Liver 20 437 41... [Pg.234]

Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S (2007) Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 126 245-249 Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di BiscegUe A, Peters M, Waggoner JG, Park Y, Jones EA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315 1575-1578 Horiike N, Onji M (2003) Combination therapy with interferon-alpha and ribavirin as im-munomodulators in patients with chronic hepatitis C. J Gastroenterol 38 302-304... [Pg.234]

Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G (2002) Ribavirin dosing in chronic hepatitis C application of population pharmacokinetic-pharmacodynamic models, Clin Pharmacol Ther 72 349-361... [Pg.235]

Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States an update. Clin Gastroenterol Hepatol 4 936-962 Kim KI, Sasase N, Taniguchi M, Mita K, Kinoshita K, Togitani T, Shikata M, Kimura N, Izawa S, Ohtani A, Nakao K, Muramoto Y, Kim SR, Nabeshima S, Ishii F, Tanaka K, Hayashi Y (2005) Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Int J Clin Pharmacol Res 25 71-76... [Pg.236]

Lindahl K, Stable L, Bruchfeld A, Schvarcz R (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41 275-279... [Pg.237]

Niro GA, Rosina F, Rizzetto M (2005b) Treatment of hepatitis D. J Viral Hepat 12 2-9 Niro GA, Ciancio A, Gaeta GB, SmedUe A, Marrone A, OUvero A, Stanzione M, David E, Bran-caccio G, Fontana R, Perri F, AndriuUi A, Rizzetto M (2006) Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44 713-720... [Pg.238]

Poynard T, MarceUin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 1426-1432... [Pg.239]

See other pages where Ribavirin hepatitis is mentioned: [Pg.313]    [Pg.199]    [Pg.200]    [Pg.646]    [Pg.120]    [Pg.8]    [Pg.15]    [Pg.22]    [Pg.27]    [Pg.47]    [Pg.110]    [Pg.215]    [Pg.215]    [Pg.216]    [Pg.227]    [Pg.230]    [Pg.231]    [Pg.234]    [Pg.235]    [Pg.235]    [Pg.235]    [Pg.236]    [Pg.237]    [Pg.237]    [Pg.237]    [Pg.238]    [Pg.238]    [Pg.238]   
See also in sourсe #XX -- [ Pg.356 ]

See also in sourсe #XX -- [ Pg.94 ]

See also in sourсe #XX -- [ Pg.434 ]



SEARCH



© 2024 chempedia.info